497 related articles for article (PubMed ID: 19095404)
1. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Li GY; Liu JZ; Zhang B; Wang LX; Wang CB; Chen SG
Biomed Pharmacother; 2009 Sep; 63(8):566-70. PubMed ID: 19095404
[TBL] [Abstract][Full Text] [Related]
2. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
3. [Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM].
Cai X; Chen FY; Han JY; Gu CH; Zhong H; Ouyang RR
Ai Zheng; 2004 Dec; 23(12):1611-5. PubMed ID: 15601547
[TBL] [Abstract][Full Text] [Related]
4. Reversal effect of substituted 1,3-dimethyl-1H-quinoxalin-2-ones on multidrug resistance in adriamycin-resistant K562/A02 cells.
Sun LR; Li X; Cheng YN; Yuan HY; Chen MH; Tang W; Ward SG; Qu XJ
Biomed Pharmacother; 2009 Mar; 63(3):202-8. PubMed ID: 18818047
[TBL] [Abstract][Full Text] [Related]
5. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
6. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
7. Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity.
Biscardi M; Teodori E; Caporale R; Budriesi R; Balestri F; Scappini B; Gavazzi S; Grossi A
Leuk Res; 2006 Jan; 30(1):1-8. PubMed ID: 16061283
[TBL] [Abstract][Full Text] [Related]
8. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
Ludescher C; Eisterer W; Hilbe W; Gotwald M; Hofmann J; Zabernigg A; Cianfriglia M; Thaler J
Leukemia; 1995 Feb; 9(2):350-6. PubMed ID: 7869774
[TBL] [Abstract][Full Text] [Related]
9. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR.
Tang XQ; Bi H; Feng JQ; Cao JG
Acta Pharmacol Sin; 2005 Aug; 26(8):1009-16. PubMed ID: 16038636
[TBL] [Abstract][Full Text] [Related]
10. Sensitization and apoptosis augmentation of K562/ADM cells by anti-multidrug resistance gene peptide nucleic acid and antisense oligodeoxyribonucleotide.
Wei HL; Wu YJ; Jing T; Bai DC; Ma LF
Acta Pharmacol Sin; 2003 Aug; 24(8):805-11. PubMed ID: 12904281
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.
Maslak P; Hegewisch-Becker S; Godfrey L; Andreeff M
Cytometry; 1994 Sep; 17(1):84-93. PubMed ID: 8001461
[TBL] [Abstract][Full Text] [Related]
12. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine.
Gerrard G; Payne E; Baker RJ; Jones DT; Potter M; Prentice HG; Ethell M; McCullough H; Burgess M; Mehta AB; Ganeshaguru K
Haematologica; 2004 Jul; 89(7):782-90. PubMed ID: 15257929
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.
Lancet JE; Baer MR; Duran GE; List AF; Fielding R; Marcelletti JF; Multani PS; Sikic BI
Leuk Res; 2009 Aug; 33(8):1055-61. PubMed ID: 19108889
[TBL] [Abstract][Full Text] [Related]
14. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
Liu ZL; Hirano T; Tanaka S; Onda K; Oka K
J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364
[TBL] [Abstract][Full Text] [Related]
15. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells.
Yusa K; Tsuruo T
Cancer Res; 1989 Sep; 49(18):5002-6. PubMed ID: 2569930
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a daunorubicin-resistant cell line which shows multi-drug resistance by multifactorial mechanisms.
Urasaki Y; Ueda T; Yoshida A; Fukushima T; Takeuchi N; Tsuruo T; Nakamura T
Anticancer Res; 1996; 16(2):709-14. PubMed ID: 8687117
[TBL] [Abstract][Full Text] [Related]
17. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
[TBL] [Abstract][Full Text] [Related]
18. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
Arora A; Seth K; Kalra N; Shukla Y
Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
[TBL] [Abstract][Full Text] [Related]
19. Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.
Xu WL; Shen HL; Ao ZF; Chen BA; Xia W; Gao F; Zhang YN
Leuk Res; 2006 Apr; 30(4):407-13. PubMed ID: 16219352
[TBL] [Abstract][Full Text] [Related]
20. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells.
Watanabe M; Komeshima N; Naito M; Isoe T; Otake N; Tsuruo T
Cancer Res; 1991 Jan; 51(1):157-61. PubMed ID: 1988080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
